65,437 trials
Lymphoma
Primary: Primary Analysis: Progression Free Survival (PFS): Stratified Analysis — 23.75; 40.51 months — p=0.0922
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Social Isolation · Loneliness · Caregiver Burnout
Primary: Change From Baseline in Loneliness at Post Intervention — 51.125000; 53.000000 score on a scale
Persistent Post Traumatic Headache · Mild Traumatic Brain Injury
Primary: Change From Baseline in the Number of Moderate-to-Severe Headache Days Per Month — -2.5; 2.3; -3.9; 1.2 Days per Month
Anxiety · Burns
Primary: Number of Participants Successfully Completing the Pilot Trial Without Adverse Effects — 16 Participants
CMV Disease
Primary: Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease Through 52 Weeks Post-transplant — 10.4; 11.8 Percentage of Participants
Structural Anomalies · Cardiac Anomalies · Central Nervous System Anomalies
Primary: Diagnostic Yield of Prenatal Exome in Patients With Fetal Structural Anomalies — 60 Participants
Hematopoietic Stem Cells
Primary: Intestinal aGvHD-Free Survival After Allo-HSCT by +180 Days — NA; NA days — p=<0.001
Fibromyalgia
Primary: Change in Ratio of Choline/ Creatine (CHO/CR) in the Brain From Baseline to 3 Hrs Post-endotoxin Administration — -.0021; -.0058 ratio
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Remission at Week 8 — 5; 4; 5; 11 Participants
HIV Infections
Primary: Frequency of Grade 2 or Higher Adverse Events (AEs) — 1; 2; 0 Participants
Fibrosing Alopecia · Frontal Fibrosing Alopecia · Central Centrifugal Cicatricial Alopecia
Primary: Total Area Hair Count (Frontal) — 86.8 Count per cm^2
Acne Scars - Mixed Atrophic and Hypertrophic
Primary: Mean Change From Baseline in Erythema — -1.687; 5.730 units on a scale
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver Disease
Primary: Percent Change From Baseline (CFB) in Percent (%) Liver Fat as Assessed Via Magnetic Resonance Imaging Using Proton Density Fat Fraction Acquisition (MRI-PDFF) at Week 6…
Alzheimer Disease
Primary: Count of Treatment Emergent Adverse Events (TEAEs) — 2; 2; 2; 1 Participants